The REGN chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the REGN chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The REGN stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View REGN Detailed Price Forecast - CNN Money||View REGN Detailed Summary - Google Finance|
|View REGN Detailed Summary - Yahoo! Finance||View REGN Stock Research & Analysis - Zacks.com|
|View REGN Trends & Analysis - Trade-Ideas||View REGN Major Holders - Barrons|
|View REGN Call Transcripts - NASDAQ||View REGN Breaking News & Analysis - Seeking Alpha|
|View REGN Annual Report - CompanySpotlight.com||View REGN OTC Short Report - OTCShortReport.com|
|View REGN Fundamentals - TradeKing||View REGN SEC Filings - Bar Chart|
|View Historical Prices for REGN - The WSJ||View Performance/Total Return for REGN - Morningstar|
|View the Analyst Estimates for REGN - MarketWatch||View the Earnings History for REGN - CNBC|
|View the REGN Earnings - StockMarketWatch||View REGN Buy or Sell Recommendations - MacroAxis|
|View the REGN Bullish Patterns - American Bulls||View REGN Short Pain Metrics - ShortPainBot.com|
|View REGN Stock Mentions - StockTwits||View REGN Stock Mentions - PennyStockTweets|
|View REGN Stock Mentions - Twitter||View REGN Investment Forum News - Investor Hub|
|View REGN Stock Mentions - Yahoo! Message Board||View REGN Stock Mentions - Seeking Alpha|
|View Insider Transactions for REGN - SECform4.com||View Insider Transactions for REGN - Insider Cow|
|View REGN Major Holdings Summary - CNBC||View Insider Disclosure for REGN - OTC Markets|
|View Insider Transactions for REGN - Yahoo! Finance||View Institutional Holdings for REGN - NASDAQ|
|View REGN Stock Insight & Charts - FinViz.com||View REGN Investment Charts - StockCharts.com|
|View REGN Stock Overview & Charts - BarChart||View REGN User Generated Charts - Trading View|
Biogen Surpassed Estimates in Q3 2018, Reports Strong Growth
Posted on Tuesday October 23, 2018
Biogen (BIIB), a leading biotechnology company, released its third-quarter earnings on October 23. Biogen surpassed Wall Street analysts’ estimates for EPS and revenues during the quarter. Biogen reported non-GAAP diluted EPS of $7.40 on revenues of ~$3.44 billion.
Is a Beat in Store for Bristol-Myers (BMY) in Q3 Earnings?
Posted on Monday October 22, 2018
Bristol-Myers (BMY) is scheduled to report third-quarter earnings on Oct 25.
FDA Approves Asthma Indication for Dupixent® (dupilumab)
Posted on Monday October 22, 2018
TARRYTOWN, N.Y. and PARIS, Oct. 22, 2018 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced the U.S. Food and Drug Administration has approved Dupixent® (dupilumab) as an add-on maintenance therapy in patients with moderate-to-severe asthma aged 12 years and older with an eosinophilic phenotype or with oral corticosteroid-dependent asthma.
Sanofi drug Dupixent wins U.S. FDA approval to treat asthma
Posted on Friday October 19, 2018
France's Sanofi SA said on Friday eczema drug Dupixent was approved by the U.S. Food and Drug Administration as an additional maintenance therapy in patients with two types of asthma. Dupixent, co-developed with U.S.-based Regeneron, received approval to treat patients with eosinophilic asthma and those dependent on anti-inflammatory steroids. The drug, a key revenue driver for Sanofi, had worldwide sales of 176 million euros ($202.5 million) in the second quarter of 2018, of which 151 million euros came from the United States.